Overview
P21 is a synthetic 6-amino-acid peptide (Ada-K-D-A-L-Ada) designed as a mimetic of a region of ciliary neurotrophic factor (CNTF), a neurotrophic cytokine known to promote neurogenesis and protect neurons in models of neurodegenerative disease. CNTF itself has therapeutic potential but causes appetite suppression and weight loss through hypothalamic effects, limiting clinical utility.
P21 was developed by the laboratory of Iqbal Grundke-Iqbal and Khalid Iqbal at the New York State Institute for Basic Research with the goal of retaining the neurogenic and cognitive benefits of CNTF while eliminating its anorectic effects. The peptide selectively activates the CNTF receptor signaling cascade in hippocampal neural stem cells, enhancing adult neurogenesis in the dentate gyrus.
In transgenic mouse models of Alzheimer's disease (3xTg-AD, APP/PS1), P21 administration improved spatial memory, reduced amyloid pathology, decreased tau hyperphosphorylation, and increased markers of synaptic plasticity. In aged wild-type mice, P21 has been reported to restore cognitive function comparable to younger animals. These preclinical findings have generated interest in the peptide as a candidate disease-modifying therapy for Alzheimer's disease and age-related cognitive decline.
Despite encouraging animal data, P21 has not entered clinical trials, has not been characterized pharmacologically in humans, and is sold only as a research chemical. Pharmacokinetics, bioavailability, and safety in humans are unknown. There is no published evidence that P21 is effective or safe for human use.
Quick facts
- Mechanism
- CNTF mimetic peptide promoting neurogenesis and synaptic plasticity without anorectic effects
- Primary use
- Neurogenesis, cognition, and Alzheimer's research
- Evidence
- limited
- FDA
- Not approved
- Route
- Subcutaneous or intranasal (research only)
- Typical results
- Increased hippocampal neurogenesis and improved cognition in rodent models over 2–8 weeks; no published human trials
Chemical information
P21 (C₃₀H₅₄N₆O₅) is a cognition compound with a molecular weight of 578.3 g/mol. Its structural characteristics underpin its biological activity in cognitive function and neural health.
How P21 works
P21 is thought to engage the CNTF receptor complex (CNTFRα–LIFR–gp130) on neural stem cells and neurons, activating the JAK/STAT3 pathway and downstream pro-neurogenic transcriptional programs. Activation increases proliferation of hippocampal neural progenitors and supports survival, differentiation, and integration of newborn neurons into existing circuits. Unlike full-length CNTF, P21 does not engage the hypothalamic CNTF–STAT3 anorectic pathway, leaving feeding behavior unaffected in animal studies.
Mechanistic studies show that P21 increases expression of BDNF and other neurotrophic factors in the hippocampus, increases dendritic complexity and spine density on CA1 pyramidal neurons, and enhances long-term potentiation (LTP). In Alzheimer's models, P21 also reduces glycogen synthase kinase-3β (GSK-3β) activity, decreasing tau hyperphosphorylation and amyloid precursor protein processing.
Adult neurogenesis in the dentate gyrus is associated with pattern separation, mood regulation, and cognitive flexibility. Pharmacologic enhancement of this process has been a long-standing therapeutic goal for Alzheimer's disease, depression, and age-related cognitive decline. P21 represents one of several small-molecule and peptide approaches in this space.
Intranasal administration of P21 has been investigated in rodents as a way to bypass the blood-brain barrier and achieve CNS concentrations sufficient for activity. Subcutaneous dosing has also been used in preclinical studies. Human-relevant pharmacokinetic data are not available.
- CNTF receptor activation: Engages CNTFRα-LIFR-gp130 complex on neural progenitors
- JAK/STAT3 signaling: Drives pro-neurogenic gene expression
- Hippocampal neurogenesis: Increases proliferation and survival of dentate gyrus neurons
- BDNF upregulation: Enhances synaptic plasticity and dendritic complexity
- No anorectic effect: Lacks hypothalamic appetite suppression seen with native CNTF
Pharmacokinetics
| Parameter | Value | Significance |
|---|---|---|
| Molecular Mass | ~578 g/mol | Small peptide amenable to multiple delivery routes |
| Plasma half-life | Not characterized in humans | Limits clinical translation |
| Oral bioavailability | Negligible (peptide degradation in GI tract) | Requires parenteral or intranasal delivery |
| Intranasal CNS access | Reported in rodent studies | Potential route for clinical development |
| Metabolism | Enzymatic peptide hydrolysis | No CYP interactions expected |
Dosing & administration
P21 dosing varies by indication and individual factors. No FDA-approved dosing exists for this compound; protocols in the literature derive from limited clinical or preclinical data and practitioner experience.
Any use should be conducted under qualified medical supervision with appropriate monitoring of safety markers.
Important: These dosing ranges are not FDA-approved. Any use should be under qualified medical supervision.
Side effects & safety
Safety data for P21 is primarily derived from preclinical studies and limited human data. Long-term effects in humans remain incompletely characterized.
Common
- • Not characterized in humans
- • Injection-site reactions reported anecdotally
- • Mild headache reported by some users
- • No anorectic effects in animal models (in contrast to CNTF)
Serious / potential risks
- • Unknown human safety profile
- • Theoretical immune activation through gp130 cytokine family signaling
- • Unknown long-term effects on neural stem cell pools
- • Risk of unwanted CNTF-pathway off-target effects
- • Quality and identity of research-chemical material is highly variable
Drug interactions
| Medication | Interaction | Recommendation |
|---|---|---|
| Other neurogenic agents (SSRIs, lithium) | Potential additive effects on neurogenesis | Theoretical only; no clinical data |
| Anticholinesterases (donepezil, rivastigmine) | Different mechanisms; potentially complementary in AD models | Not studied clinically |
| Glucocorticoids | Suppress neurogenesis and may antagonize P21 effects | Theoretical; consider in research design |
| Immunomodulators | Unknown effects on CNTF receptor signaling | Avoid combinations in research without supervision |
Storage & handling
Lyophilized (powder)
- • Store at -20°C to 4°C (freezer or refrigerator)
- • Protect from light and moisture
- • Stable for 12–24 months when stored properly
- • Keep in original sealed container until reconstitution
Reconstituted solution
- • Refrigerate at 2–8°C after reconstitution
- • Use bacteriostatic water for multi-dose reconstitution
- • Typical stability: 14–28 days refrigerated
- • Do not freeze reconstituted solution
Cost & availability
| Source | Cost | Notes |
|---|---|---|
| Research suppliers | Varies widely | Quality and purity vary significantly between sources |
| Compounding pharmacies | Prescription required | Higher quality assurance and purity testing |
The bottom line
P21 is a cognition compound with research interest in neurogenesis, cognition, cntf, memory. While preclinical evidence is encouraging, it remains investigational and is not FDA-approved. Any use should be under qualified medical supervision.
Best for
- • Researchers studying cognitive function and neural health
- • Individuals interested in neurogenesis under medical guidance
Not for
- • Self-administration without medical supervision
- • Pregnant or breastfeeding individuals
- • Individuals with contraindicated conditions
Related compounds
Dihexa
HGF/Met-pathway peptide with strong synaptogenic effects
Semax
BDNF-modulating neuropeptide with cognitive benefits
Cerebrolysin
Neurotrophic peptide mixture with cognitive and stroke-recovery data
PE-22-28
Spadin-derived peptide with antidepressant and neurogenic effects
Frequently asked questions
References
- [1] Blanchard J, Wanka L, Tung YC, et al.. Pharmacologic reversal of neurogenic and cognitive deficits in mouse models of Alzheimer's disease by neurotrophic peptide. Acta Neuropathol (2010). doi: 10.1007/s00401-010-0689-7 PMID: 20512364
- [2] Bolognin S, Buffelli M, Puoliväli J, Iqbal K.. Rescue of cognitive-aging by administration of a neurogenic and/or neurotrophic compound. Neurobiol Aging (2014). doi: 10.1016/j.neurobiolaging.2014.05.026 PMID: 24996240
- [3] Kazim SF, Iqbal K.. Neurotrophic factor small-molecule mimetics mediated neuroregeneration and synaptic repair. Mol Neurodegener (2016). doi: 10.1186/s13024-016-0119-y PMID: 27484226